Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imgatuzumab in advanced cutaneous squamous cell carcinoma
NCT04985825Phase 2Withdrawn
- Sponsor
- PegaOne
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of imgatuzumab in cutaneous squamous cell carcinoma (cSCC), sponsored by PegaOne. Primary endpoint: Overall Response Rate at 24 months. Planned start Dec 2021; status: withdrawn.
02
Drugs
imgatuzumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04985825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985825.